# Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

> **NCT03915132** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 47 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Nimotuzumab
- **RADIATION:** VMAT

## Key facts

- **NCT ID:** NCT03915132
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-01
- **Primary completion:** 2020-05-01
- **Final completion:** 2022-05-01
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2021-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03915132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03915132, "Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT03915132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*